{"id":440554,"date":"2026-10-21T20:40:15","date_gmt":"2026-10-21T13:40:15","guid":{"rendered":"https:\/\/www.swingfish.trade\/blog\/market-news\/inmune-bio-establishes-global-commercialization-framework-for-ebstrocel-through-strategic-agreement-with-uniphar-440554\/"},"modified":"2026-10-21T20:40:15","modified_gmt":"2026-10-21T13:40:15","slug":"inmune-bio-establishes-global-commercialization-framework-for-ebstrocel-through-strategic-agreement-with-uniphar","status":"publish","type":"post","link":"https:\/\/www.swingfish.trade\/blog\/market-news\/inmune-bio-establishes-global-commercialization-framework-for-ebstrocel-through-strategic-agreement-with-uniphar-440554\/","title":{"rendered":"INmune Bio Establishes Global Commercialization Framework for Ebstrocel\u2122 Through Strategic Agreement with Uniphar"},"content":{"rendered":"
\n

INmune Bio Inc.
\n (NASDAQ: INMB) (the \u201cCompany\u201d), a late-stage biotechnology company focused on
\n inflammation and immunology, today announced that it has entered into a Master
\n Services Agreement with Uniphar Durbin Ireland Limited (\u201cUniphar\u201d) establishing
\n a scalable framework to support international access, distribution and
\n commercialization of Ebstrocel\u2122, the Company\u2019s allogeneic stromal cell therapy
\n for Recessive Dystrophic Epidermolysis Bullosa (RDEB). INmune Bio initially
\n intends to use the framework to pursue named-patient access in selected
\n European countries and in the Middle East and North Africa (MENA), subject to
\n applicable law and country-specific statements of work. The relationship may
\n subsequently expand across Europe and other territories by mutual agreement.<\/p>\n

The Company expects
\n named-patient access to be an important component of its international
\n commercialization strategy for Ebstrocel\u2122. Where permitted by local law and
\n implemented through statements of work, this pathway may allow physicians to
\n request Ebstrocel\u2122 for individual eligible patients before local marketing
\n approval or broad commercial availability.<\/p>\n

The Uniphar framework
\n is designed to provide the Company with scalable international commercial
\n infrastructure, beginning with named-patient supply, and potentially expanding
\n to broader commercial distribution as regulatory approvals, pricing and reimbursement
\n are secured in individual countries. Depending on the services agreed in
\n individual statements of work, Uniphar may support regulatory feasibility
\n assessments, market access, product storage and distribution,
\n healthcare-provider and treatment-site onboarding, order-to-cash services,
\n medical information, pharmacovigilance support and end-to-end shipment
\n tracking. By leveraging Uniphar\u2019s established infrastructure rather than
\n building country-by-country capabilities internally, the Company believes this
\n model provides a capital-efficient path to establish Ebstrocel\u2122\u2019s international
\n commercial footprint and scale as additional markets become available.<\/p>\n

\u201cThis agreement marks
\n an important step in moving Ebstrocel\u2122 from clinical development toward
\n commercialization and bringing Ebstrocel to patients internationally,\u201d said
\n David Moss, Chief Executive Officer of INmune Bio. \u201cUniphar provides access to
\n established market-access, distribution and order-to-cash capabilities across
\n multiple international markets without requiring INmune Bio to build those
\n capabilities country by country. We believe this provides a capital-efficient
\n way to pursue named-patient opportunities in appropriate markets while building
\n the physician relationships, treatment-center experience and commercial
\n infrastructure needed to support broader international
\n commercialization.\u201d\u00a0\u201cWe are pleased to partner with INmune Bio as it
\n prepares Ebstrocel for international commercialization,\u201d said Ruth Rostron,
\n Head of Expanded Access at Uniphar. \u201cUniphar has built an integrated global
\n platform to help innovative medicines navigate the complexities of
\n international access, distribution and commercialization. We believe our
\n infrastructure and experience are well suited to support INmune Bio\u2019s strategy
\n for Ebstrocel, beginning with named-patient access opportunities and expanding
\n as the product progresses through its regulatory and commercial journey.\u201d<\/p>\n

About Ebstrocel\u2122<\/p>\n

Ebstrocel\u2122 (pobistrocel)
\n is INmune Bio\u2019s investigational, pooled, allogeneic, human umbilical
\n cord-derived mesenchymal stromal cell therapy being developed through the
\n Company\u2019s CORDStrom\u2122 platform for the treatment of RDEB. The platform is
\n designed to address donor variability and manufacturing inconsistency.
\n Ebstrocel\u2122 is investigational and has not been approved by the FDA, MHRA, EMA
\n or any other regulatory authority.<\/p>\n

About Uniphar Plc.<\/p>\n

Uniphar is a trusted
\n global partner to pharma, medtech and biotech, delivering solutions that
\n connect medicines and technologies with patients worldwide. With over 57 years
\n of experience and partnerships with 200+ multinational clients, Uniphar
\n combines deep expertise, global infrastructure and market insight to meet the
\n evolving needs of the life sciences sector.<\/p>\n

Uniphar Pharma
\n integrates Development, Clinical, Access, Medical, Commercial, Distribution and
\n Global Sourcing to support the full product lifecycle \u2013 from early-stage
\n research through to commercialization and beyond. Uniphar\u2019s unified platform
\n spans regulatory strategy, clinical trial support, medical affairs, market
\n access, patient engagement, commercial services, distribution and supply chain.<\/p>\n

Operating across 160
\n countries with a global team of 3,600+, Uniphar bridges manufacturers,
\n healthcare providers, and patients \u2014 accelerating access to innovative
\n therapies, improving patient outcomes, and delivering value across the
\n healthcare ecosystem.<\/p>\n

From molecule to
\n market and beyond.<\/p>\n

About INmune Bio
\n Inc.<\/p>\n

INmune Bio Inc. https:\/\/www.inmunebio.com\/ is a
\n publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on
\n developing treatments that target the innate immune system to fight disease.
\n Moving beyond early-stage exploration, the Company\u2019s clinical-development
\n strategy centers on advanced precision medicine, matching drug mechanisms
\n directly to patient biology to optimize clinical outcomes.<\/p>\n

INmune Bio is actively
\n advancing two late-stage product platforms toward registrational milestones:<\/p>\n